On March 12, 2008 BioInvent reported that it has signed a deal with Bayer HealthCare related to the discovery and development of antibody products. Under the terms of the agreement, Bayer HealthCare will have a non-exclusive research licence for the use of BioInvent’s proprietary n-CoDeR library for the discovery of human monoclonal antibodies (Press release BioInvent, MAR 12, 2013, http://www.bioinvent.com/investors/press-releases/release.aspx?releaseid=337691 [SID:1234500559]). BioInvent, in addition to its n-CoDeR technology, will provide at BioInvent access to an extended antibody technology suite including BioInvent’s proprietary selection processes, streamlined robotics and Immunoglobulin transient expression technology. Bayer HealthCare will fund all such activities.
As well as undisclosed license fees, BioInvent will receive additional milestone payments and escalating royalties on sales of any products commercialised. The agreement allows for up to 14 antibody products to be developed.
The n-CoDeR library contains approximately 2 x 1010 highly diverse fully human antibody fragments that have been created using BioInvent’s patented approach, generating antibodies with good affinities and selectivities.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!